Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer

NCT01349959 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01349959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01349959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
August 15, 2011
Completion date
November 7, 2023
Enrollment
58 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

male breast carcinoma, recurrent breast carcinoma, stage iiic breast cancer ajcc v7, stage iv breast cancer ajcc v6 and v7, triple-negative breast carcinoma